Resveratrol-pretreated ADSC-CM alleviates liver oxidative damage in mice by mediating the Sirt1/Nrf2 axis.
Feng J., Chang C., Zhang Z., Hou L., Zhong Y., Zhang T.
Animal Study, published in Tissue Cell (2025) — summary generated from the PubMed abstract.
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Animal Study
- Journal
- Tissue Cell (2025)
- Country
- Scotland
- Reported sample size
- —
- Source database
- PubMed
- PMID
- 40902514
- DOI
- 10.1016/j.tice.2025.103099
Abstract (original English)
Chronic liver injury is a prevalent pathological condition. Adipose-derived stem cell-conditioned medium (CM) has demonstrated efficacy in attenuating liver injury. Resveratrol (Res) pretreatment enhances the therapeutic effect of ADSCs, but whether it can enhance the protective effect of CM against CCl 4 -induced liver injury is unknown. Therefore, we investigated the effects of CM and Res-pretreated adipose-derived stem cell-conditioned medium (R-CM) on liver structure, fibrosis, proliferation, oxidative stress, and mitochondrial pathway apoptosis in CCl 4 -injured mice and further explored the underlying regulatory mechanism of the antioxidant effects of Res on CM. These findings indicated that R-CM was more effective than CM in mitigating CCl 4 -induced liver injury, fibrosis, oxidative stress, and apoptosis. Moreover, we found that Res enhances the antioxidant capacity of CM by mediating the Sirt1/Nrf2 axis. Overall, our study demonstrated that CM derived from ADSCs could alleviate CCl 4 -induced hepatic oxidative stress, and we found that Res could increase the antioxidant capacity of CM, which is closely related to the regulation of the Sirt1/Nrf2 pathway.
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
- • This is preclinical work; animal or laboratory results cannot be applied to humans.
Evidence level
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.